HDAC Inhibitors

 |  Home  |  Vorinostat  |  CI-994  |  MS-275  |  BML-210  |  M344  |  NVP-LAQ824  |  Panobinostat  |  Mocetinostat  |  PXD101  | 

Trichostatin A

Trichostatin A (TSA) is an organic compound that inhibits both class I and II HDACs (histone deacetylases). TSA has potent dose-dependent antitumor activity against breast cancer in vitro and in vivo, strongly supporting HDAC as a molecular target for anticancer therapy in breast cancer.

Trichostatin-A

IUPAC Name: (2E,4E,6R)-7-(4-dimethylaminophenyl)-N-hydroxy-4,6-dimethyl-7-oxohepta-2,4-dienamide
Molecular Weight: 302,38 g/mol
Molecular Formula: C17H22N2O3
SMILES: CN(C)c1ccc(cc1)C(=O)C(C)C=C(C)C=CC(=O)NO
Canonical SMILES: CC(C=C(C)C=CC(=O)NO)C(=O)C1=CC=C(C=C1)N(C)C
InChIKey Identifier: RTKIYFITIVXBLE-QEQCGCAPSA-N
CAS Number: 58880-19-6
Melting point: 141-143°C
Solubility: DMSO, Ethanol
2D Molfile: Get the molfile
Synonyms: TSA

TSA suppresses the activity of HDAC leading to an increase in histone acetylation. This histone acetylation induces an enhancement of the expression of specific genes that elicit extensive cellular morphologic and metabolic changes, such as growth arrest, differentiation and apoptosis.

Trichostatin A has been shown to induce apoptosis in many cancer cells at submicromolar concentrations with very low toxicity toward normal cells.

References:
1) Roh MS, Kim CW, Park BS, Kim GC, Jeong JH, Kwon HC, Suh DJ, Cho KH, Yee SB, Yoo YH. Mechanism of histone deacetylase inhibitor Trichostatin A induced apoptosis in human osteosarcoma cells. Apoptosis. 2004;9:583–589.
2) Vigushin DM, Ali S, Pace PE, Mirsaidi N, Ito K, Adcock I, Coombes RC. Trichostatin A is a histone deacetylase inhibitor with potent antitumor activity against breast cancer in vivo. Clin Cancer Res. 2001 Apr;7(4):971-6.

HDACs


 |  CBHA  |  PCI-24781  |  ITF2357  |  Valproic Acid  |  Trichostatin A  |  Sodium Butyrate  |